3 results
The primary objective of the study is:Evaluate the safety of 6.0 mg/kg and 12 mg/kg SM101 per week in SLE patients with or without a history of lupus nephritis.The Secondary objective is:Evaluate the efficacy and pharmacokinetics (PK) of 6.0 mg/kg…
This study is designed to confirm the safety and efficacy of PLASOMA after CE marking:1. in a larger population,2. in a more diverse population, consisting also of non-diabetic wound types, and3. including long-term safety.and to determine the…
This study is designed to examine beneficial effects of PLASOMA treatment compared to the standard of care on chronic venous leg ulcers (VLU) that match the size of the plasma area of the pad.The intention is that the data obtained with this study…